Satellite symposium at the
11th Congress of the European Association of Dermato-Oncology
Advancing the science of CTCL treatment with targeted therapy
Wednesday 28 October 2015 18:00–19:00
Palais du Pharo, Marseille, France

Chalid Assaf

Academic Hospital of the RWTH University Aachen
Aachen, Germany

Chalid Assaf is Director of the Department of Dermatology at the HELIOS Klinikum Krefeld, Academic Hospital of the RWTH University Aachen in Germany, a post he has held since 2009. Professor Assaf studied at the medical school of the Free University of Berlin, Germany, with a fellowship at the John Radcliffe Hospital, University of Oxford, UK, and was awarded his MD in 1997, then started an illustrious career. An internship at the Department of Pathology at the Benjamin Franklin Medical School of the Free University of Berlin, Germany, was followed by a residency and a specialist post in the Department of Dermatology and Venereology at the same hospital; he was then appointed Head of the Lymphoma Section of the Skin Cancer Center and, in 2008, as Assistant Professor, both at the Charité – Universitätsmedizin in Berlin.

Professor Assaf was awarded a PhD for his thesis "Development of TCR-beta PCR for analysis of T-cell lymphomas in combination with Genescan analysis" in 2001. He has published widely, with more than 83 peer-reviewed publications in journals including Lancet Oncology, British Journal of Haematology, Journal of Clinical Oncology, Blood, Journal of Investigative Dermatology, and British Journal of Dermatology, as well as being a reviewer for many journals. Scientific Society membership includes the International Society of Cutaneous Lymphoma (ISCL) and the European Organisation for Research and Treatment of Cancer (EORTC), and he has received many awards, including the Berlin Foundation of Dermatology Research Award, First Prize, in 2012.

Chair:

Chalid Assaf
Germany
Faculty:

Martine Bagot
France

Reinhard Dummer
Switzerland
This meeting is an
Excerpta Medica activity.
logos
Support for this educational activity is provided by
Takeda Oncology.
logos